Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail targets Hard-to-Treat myeloma

NCT ID NCT03798678

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 33 times

Summary

This early-phase trial tests a new drug (CB-839 HCl) combined with two standard treatments (carfilzomib and dexamethasone) in 36 adults whose multiple myeloma has come back or stopped responding to prior therapy. The main goal is to find the safest dose and check for side effects. The approach aims to block a key enzyme cancer cells need to grow, potentially making the standard drugs work better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.